Porton Pharma Solutions and Codexis Launch Global Partnership

REDWOOD CITY, Calif. & CHONGQING, China–(BUSINESS WIRE)–Codexis,
Inc. (NASDAQ: CDXS) and Porton
Pharma Solutions, Ltd. (SZSE: 300363) announce a strategic
collaboration to deploy Codexis’ world-leading biocatalyst technology
within Porton’s global custom intermediate and active pharmaceutical
ingredients (API) development and manufacturing business. The
partnership will accelerate the creation and commercialization of new,
low-cost, sustainable manufacturing processes, exploiting the benefits
of biocatalysts to a growing number of the world’s small molecule
pharmaceuticals.

Under the terms of the collaboration, Codexis will license core elements
of its biocatalyst technologies to Porton, including its proprietary
biocatalyst libraries, high-throughput screening and enzyme
manufacturing know-how. Codexis will also provide preferential access to
its CodeEvolver® protein engineering platform technology for
the creation of new biocatalytic process solutions. Porton will install
new operations to drive adoption and optimal application of these
biocatalyst technologies into its custom contract development and
manufacturing (CDMO) offerings to global pharmaceutical customers.
Additionally, Porton pledges financial commitments to utilize Codexis’
CodeEvolver® protein engineering platform technology.

The partnership reinforces the benefits of reduced costs, enhanced
sustainability and improved product quality that biocatalysts can
deliver to the manufacturing of the world’s small molecule
pharmaceuticals. These benefits are already impacting a growing set of
the world’s drug manufacturing processes and have earned Codexis three
U.S. EPA Presidential Green Chemistry Challenge awards for its
biocatalysts’ contributions in these commercial-scale drug manufacturing
innovations.

“Technological leadership is central to our strategy to grow and deliver
value to our pharmaceutical clients around the globe,” said Oliver
Ju, chairman and CEO at Porton Pharma Solutions. “We believe that
biocatalysis is the most impactful technology to improve the future of
pharmaceutical manufacturing, and there is not a more capable player to
partner with than Codexis.”

“We are delighted to establish this unique partnership with Porton,”
said John
Nicols, president and CEO of Codexis. “Given Porton’s significant
and fast-growing presence as a leading global CDMO, we will now be able
to reach a greater share of the world’s pharmaceutical manufacturing
market.”

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its
proprietary CodeEvolver® technology to develop proteins for a
variety of applications, including as biocatalysts for the commercial
manufacture of pharmaceuticals, fine chemicals and industrial enzymes,
and enzymes as biotherapeutics and for use in molecular diagnostics.
Codexis’ proven technology enables improvements in protein performance,
meeting customer needs for rapid, cost-effective and sustainable
manufacturing in multiple commercial-scale implementations of
biocatalytic processes. For more information, see www.codexis.com.

About Porton Pharma Solutions

Porton Pharma Solutions is an industry-leading partner and provider of
custom active pharmaceutical ingredient (API) development and
manufacturing services to the global drug industry (SZSE, Stock Code
300363). Backed by more than 1,700 customer-centric employees,
cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP
production sites and marketing offices located across Asia, North
America and Europe, Porton helps its customers more efficiently deliver
improved health outcomes to their patients through chemical process
innovation, rapid scale-up and high-quality, cost-effective manufacture
of APIs and/or drug intermediates. Learn more by visiting www.porton.cn.

Forward-Looking Statements

To the extent that statements contained in this press release are not
descriptions of historical facts regarding Codexis, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including
Codexis’ expectations regarding its strategic global partnership with
Porton for the creation and commercialization of new, low cost
sustainable manufacturing processes. You should not place undue reliance
on these forward-looking statements because they involve known and
unknown risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual results.
Factors that could materially affect actual results include, among
others: Codexis’ dependence on its licensees and collaborators; Codexis’
dependence on a limited number of products and customers in its
biocatalysis business; potential adverse effects to Codexis’ business if
its customers’ pharmaceutical or food products are not received well in
the markets; risks, uncertainties and costs associated with the
successful development of biotherapeutic candidates, including obtaining
development partners for its biotherapeutic programs and progressing
such programs to clinical trials and regulatory approvals; Codexis’
ability to develop and commercialize new products for the biocatalysis
markets; Codexis’ dependence on a limited number of contract
manufacturers for large-scale production of its enzymes; Codexis’
ability to deploy its technology platform in new market spaces,
including the fine chemicals, therapeutics and in vitro molecular
diagnostics markets; Codexis’ ability to comply with the terms of its
credit facility and its associated debt service obligations; Codexis’
need for additional capital in the future in order to expand its
business or to adjust for market conditions or strategic considerations,
which may involve Codexis entering into equity offerings, debt
financings, credit facilities and/or strategic collaborations; Codexis’
dependence on key personnel; Codexis’ ability to establish and maintain
adequate protection for intellectual property, trade secrets and other
proprietary rights covering its technologies; and any claims by third
parties that Codexis is infringing their intellectual property rights or
other proprietary rights. Additional information about factors that
could materially affect actual results can be found in Codexis’ Annual
Report on Form 10-K filed with the Securities and Exchange Commission
(“SEC”) on March 15, 2018 and Codexis’ other periodic reports filed with
the SEC, including under the caption “Risk Factors.” Codexis expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required by law.

Contacts

Codexis Contacts:
Investors
LHA Investor
Relations
Jody Cain, +1 310-691-7100
[email protected]
or
Media
SCORR
Marketing
Lea Studer, +1 308-237-5567
[email protected]
or
Porton
Pharma Solutions Contact:
Helen Pi
Head of General Office
[email protected]